Cytoreductive Nephrectomy

In this video, Farshid Sadeghi, MD, discussed data from the Cyto-KIK trial on renal cell carcinoma at American Urological Association Annual Meeting.

In this video, Mark W. Ball, MD, discusses the ongoing SWOG S1931 study assessing the use of immune checkpoint inhibitors with or without cytoreductive nephrectomy in patients with renal cell carcinoma.

Adjuvant pembrolizumab prolonged DFS compared with placebo for patients with renal cell carcinoma who underwent nephrectomy with or without resection of metastatic lesions, according to the agent’s manufacturer.

Cytoreductive nephrectomy may extend OS for a well-selected population of patients with metastatic renal cell carcinoma, according to study results published in Cancer.